Leave message
Can’t find what you’re looking for?
Fill out this form to inquire about our custom protein services!
Inquire about our Custom Services >>
This protein carries no "tag".
The protein has a calculated MW of 85.5 kDa. The protein migrates as 90-116 kDa when calibrated against Star Ribbon Pre-stained Protein Marker under reducing (R) condition (SDS-PAGE) due to glycosylation.
>95% as determined by SDS-PAGE.
>95% as determined by SEC-MALS.
Lyophilized from 0.22 μm filtered solution in 50 mM HEPES, 150 mM NaCl, pH7.5 with trehalose as protectant.
Contact us for customized product form or formulation.
Please see Certificate of Analysis for specific instructions.
For best performance, we strongly recommend you to follow the reconstitution protocol provided in the CoA.
For long term storage, the product should be stored at lyophilized state at -20°C or lower.
Please avoid repeated freeze-thaw cycles.
This product is stable after storage at:
Human DPPIV, Tag Free on SDS-PAGE under reducing (R) condition. The gel was stained with Coomassie Blue. The purity of the protein is greater than 95% (With Star Ribbon Pre-stained Protein Marker).
The purity of Human DPPIV, Tag Free (Cat. No. DP4-H5211) is more than 95% and the molecular weight of this protein is around 190-220 kDa verified by SEC-MALS.
Measured by its ability to cleave the fluorogenic peptide substrate, Gly-Pro-7-amido-4-methylcoumarin (GP-AMC). The specific activity is >11000 pmol/min/µg (QC tested).
Emerging VoCs, Omicron, Delta, Beta, Alpha mutants and so on, including RBD, S trimer, S1, NTD, NP, etc. These mutants are of high purity and bioactivity and can be used to evaluate the efficacy of the antibodies and vaccination.
ACROBiosystems developed a series of GMP grade cytokines under the GMP grade quality management system. Those products are all suitable for T/NK cell generation, activation, and proliferation in cell therapy research.
50+ targets designed for CAR detection, including PE/FITC/biotin labeled proteins. The key reagents for CD19 and BCMA were FDA DMF filed which can support your IND, NDA and BLA process.
GMP grade cytokines, reagents for cell activation, gene edition, DNA/RNA removal, etc. Particularly focus on product design, quality control and solution-based support to link each phase of your cell and gene therapy journey.
Full length multi-pass TPs with stabilized structure and high bioactivity for immunization, antibody screening, cell based assay and CAR detection, including hot CD20, Claudin 18.2, CD133, GPRC5D,CCR8, CCR5, etc.
CD3 proteins and a collection of for bispecific antibody development which are of high specificity and bioactivities and suitable for immunization, antibody screening.
A series of immune checkpoints including classic co-inhibitory and co-stimulatory receptors. The comprehensive catalog contains 100+ targets with various species and tags, and the high-quality proteins are in good batch-to-batch consistency.
To meet the needs of ADCs development, ACROBiosystems can provide: A variety of high-quality target proteins; MMPs/Cathepsin/uPA for cleavable linker; Anti-payload antibodies & anti-idiotypic antibodies for immunogenicity and PK analysis; SPR/BLI analytical and ADA development service.
Comprehensive collection of Fc receptor proteins, including their common variants, which can help expedite your antibody development.
The MABSOL biotinylated protein collection includes more than a hundred commonly studied drug targets and biomarker proteins.
Comprehensive cytokines including IL families, growth factors, chemokines, TNFs, etc. These products are HEK293 expressed and nearly in authentic structure, high purity and bioactivity, cell based assay/SPR/BLI verified.
To support preclinical/clinical immunogenicity and PK analysis, ACROBiosystems has developed a series of high-affinity anti-idiotypic antibodies. Our pipeline covers five hot targets including adalimum*b, rituxim*b, cetuxim*b, trastuzum*b, and bevacizum*b.
English Name | Research Code | Research Phase | Company | First Brand Name | First Approved Country | First Indication | First Approved Company | First Approved Date | Indications | Clinical Trials |
---|---|---|---|---|---|---|---|---|---|---|
Teneligliptin Hydrobromide Hydrate/Canagliflozin Hemihydrate | Approved | Mitsubishi Tanabe Pharma Corp, Daiichi Sankyo Co Ltd | Canalia | Japan | Diabetes Mellitus, Type 2 | Daiichi Sankyo Co Ltd, Mitsubishi Tanabe Pharma | 2017-07-03 | Diabetes Mellitus, Type 2 | Details | |
Gemigliptin | Approved | Details | ||||||||
Anagliptin/Metformin Hydrochloride | SK-1501 | Approved | Sanwa Kagaku Kenkyusho Co Ltd, Suzuken | Metoana | Japan | Diabetes Mellitus, Type 2 | Sanwa Kagaku Kenkyusho Co Ltd | 2018-09-21 | Diabetes Mellitus, Type 2 | Details |
Dapagliflozin Propanediol Monohydrate/Saxagliptin Hydrochloride | Approved | Astrazeneca Plc | Qtern | United States | Diabetes Mellitus, Type 2 | Astrazeneca Ab | 2016-07-15 | Diabetes Mellitus, Type 2 | Details | |
Sitagliptin/Ertugliflozin | Approved | Pfizer Pharmaceuticals Ltd (China) | Steglujan | EU | Diabetes Mellitus, Type 2 | Merck Sharp & Dohme Bv | 2017-12-19 | Diabetes Mellitus, Type 2 | Details | |
Metformin Hydrochloride/Sitagliptin Hydrochloride | Approved | Sandoz Bv | EU | Sandoz Bv | 2019-12-10 | Details | ||||
Evogliptin Tartrate/Metformin Hydrochloride | DA-1229_01 | Approved | Dong-A Pharmaceutical Co Ltd | Sugamet XR | South Korea | Diabetes Mellitus, Type 2 | Dong-A Pharmaceutical Co Ltd | 2015-12-01 | Diabetes Mellitus, Type 2 | Details |
Rosuvastatin Calcium/Gemigliptin L-tartrate Sesquihydrate | Approved | Lg Life Sciences Ltd | ZemiStatin | Diabetes Mellitus, Type 2; Dyslipidemias | Details | |||||
Teneligliptin/Pioglitazone | Approved | Glenmark Pharmaceuticals Ltd | Zita Plus Pio | India | Diabetes Mellitus, Type 2 | Glenmark Pharmaceuticals Ltd | 2022-04-25 | Diabetes Mellitus, Type 2 | Details | |
Sitagliptin Phosphate/Metformin Hydrochloride | Approved | Merck & Co Inc | Janumet, Velmetia | Mainland China | Diabetes Mellitus, Type 2 | Msd Pharma (Singapore) Pte Ltd | 2007-03-30 | Diabetes Mellitus, Type 2 | Details | |
Linagliptin/Metformin Hydrochloride | Approved | Boehringer Ingelheim Gmbh | 欧双宁, Jentadueto, Trajenta Duo, Jentadueto Xr | Mainland China | Diabetes Mellitus, Type 2 | Boehringer Ingelheim (Schweiz) Gmbh | 2012-01-30 | Diabetes Mellitus, Type 2 | Details | |
Linagliptin/Empagliflozin | BI 1356/BI 10773; BI 10773/linagliptin; BI 1356/empagliflozin; Empagliflozin/BI 1356; Linagliptin/BI 10773; BI 10773/BI 1356 | Approved | C.H. Boehringer Sohn Ag & Co. Kg | Tradiance, Glyxambi, Esgliteo | United States | Cardiovascular Diseases | Boehringer Ingelheim Gmbh | 2015-01-30 | Diabetes Mellitus, Type 2; Cardiovascular Diseases | Details |
Empagliflozin/Linagliptin/Metformin | Approved | Boehringer Ingelheim Gmbh, Eli Lilly And Company | Trijardy XR | United States | Diabetes Mellitus, Type 2 | Boehringer Ingelheim Gmbh | 2020-01-27 | Diabetes Mellitus, Type 2 | Details | |
Teneligliptin Hydrobromide Hydrate/Metformin Hydrochloride | Approved | Handok Inc | Tenelia M SR | South Korea | Diabetes Mellitus, Type 2 | Handok Inc | 2015-11-03 | Diabetes Mellitus, Type 2 | Details | |
Gemigliptin L-tartrate Sesquihydrate/Metformin Hydrochloride | Approved | Lg Life Sciences Ltd | ZemiMet SR | South Korea | Diabetes Mellitus, Type 2 | Lg Life Sciences Ltd | 2015-01-01 | Diabetes Mellitus, Type 2 | Details | |
Gemigliptin L-tartrate Sesquihydrate | LC-150444; LC-15-0444 | Approved | Lg Life Sciences Ltd | Gemiglo, Zemiglo | South Korea | Diabetes Mellitus, Type 2 | Lg Life Sciences Ltd | 2012-06-27 | Diabetes Mellitus, Type 2; Hepatic Insufficiency | Details |
Saxagliptin Hydrochloride/Metformin Hydrochloride | Approved | Astrazeneca Pharmaceutical Co Ltd | 安立格, Komboglyze, Kombiglyze Xr | Mainland China | Diabetes Mellitus, Type 2 | Astrazeneca Ab | 2010-11-05 | Diabetes Mellitus, Type 2 | Details | |
Sitagliptin Phosphate Monohydrate | ONO-5435A; ONO-5435; MK-0431; MK-431; L-000224715 | Approved | Merck Sharp & Dohme Corp | Xelevia, Ristaben, Tesavel, Glactiv, 捷诺维, Januvia | Japan | Diabetes Mellitus, Type 2 | Msd Kk | 2006-10-16 | Gastroparesis; Kidney Failure, Chronic; Diabetes Mellitus; Hyperlipidemias; Carcinoma, Hepatocellular; Inflammation; Lymphoma, Non-Hodgkin; Leukemia, Myeloid, Acute; Renal Insufficiency, Chronic; Cardiovascular Diseases; Hepatitis C; Hepatic Insufficiency; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Psoriasis; Diabetes Mellitus, Type 1; Graft vs Host Disease; Glucose Intolerance; Insulin Resistance; Coronavirus Disease 2019 (COVID-19); Myelodysplastic Syndromes; Atherosclerosis; Non-alcoholic Fatty Liver Disease; Heart Failure; Diabetes Mellitus, Type 2; Prediabetic State; Cystic Fibrosis; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; HIV Infections | Details |
Omarigliptin | MK-3102 | Approved | Merck & Co Inc | Marizev | Japan | Diabetes Mellitus, Type 2 | Merck Sharp & Dohme Corp | 2015-09-28 | Diabetes Mellitus, Type 2; Renal Insufficiency, Chronic; Diabetes Mellitus | Details |
Sitagliptin Tartrate | Approved | Heumann Pharma GmbH & Co Generica KG | Sitagliptin Heumann 25 mg Filmtabletten | EU | Heumann Pharma GmbH & Co Generica KG | 2020-12-14 | Parkinson Disease | Details | ||
Sitagliptin Hydrochloride | Approved | EU | Diabetes Mellitus, Type 2 | Laboratorios Alter Sa | 2018-11-27 | Diabetes Mellitus, Type 2 | Details | |||
Linagliptin | BI-1356; BI-1356-BS | Approved | Boehringer Ingelheim Gmbh | 欧唐宁, Ondero, Trajenta, Trayenta, Trazenta, Tradjenta | Mainland China | Diabetes Mellitus, Type 2 | Boehringer Ingelheim International Gmbh | 2011-05-02 | Prediabetic State; Diabetes Mellitus, Type 2; Albuminuria; Renal Insufficiency; Schizophrenia; Respiratory Tract Diseases; Coronavirus Disease 2019 (COVID-19); Hypertension; Endocrine System Diseases; Coronavirus Infections; Metabolic Diseases; Hepatic Insufficiency; Glucose Metabolism Disorders; Inflammation; Ventricular Dysfunction, Left; Diabetes Mellitus | Details |
Anagliptin | SK-0403; CWP-0403 | Approved | Sanwa Kagaku Kenkyusho Co Ltd | Suiny, Beskoa | Japan | Diabetes Mellitus, Type 2 | null | 2012-09-28 | Diabetes Mellitus, Type 2 | Details |
Vildagliptin | LAF-237; DSP-7238; LAF-237A; NVP-LAF-237 | Approved | Novartis Pharma Ag | 佳维乐, Equa, Jalra, Galvus, Gliptus, Xiliarx | Mainland China | Diabetes Mellitus, Type 2 | Novartis Europharm Ltd | 2007-09-25 | Diabetes Mellitus, Type 1; Prediabetic State; Diabetes Mellitus, Type 2; Renal Insufficiency; Schizophrenia; Insulin Resistance; Kidney Diseases; Dyslipidemias; Diabetes, Gestational; Diabetes Mellitus | Details |
Alogliptin Benzoate/Pioglitazone Hydrochloride | SYR-322-4833 BL | Approved | Takeda Pharmaceutical Co Ltd | Nesinaact, Oseni, Liovel, Incresync | EU | Diabetes Mellitus, Type 2 | Takeda Pharma A/S | 2011-07-01 | Diabetes Mellitus, Type 2 | Details |
Trelagliptin Succinate | TAK-472; SYR-472; SYR-111472; SYR-111472 succinate | Approved | Takeda Pharmaceutical Co Ltd | Zafatek | Mainland China | Diabetes Mellitus, Type 2 | Sichuan Kelun Pharmaceutical Co Ltd | 2015-03-26 | Diabetes Mellitus, Type 2; Diabetes Mellitus | Details |
Alogliptin Benzoate/Metformin Hydrochloride | CT-L01; CT-L-01 | Approved | Takeda Pharmaceutical Co Ltd | Inisync, Kazano, Vipdomet | Japan | Diabetes Mellitus, Type 2 | Takeda | 2013-01-25 | Diabetes Mellitus, Type 2 | Details |
Vildagliptin/Metformin Hydrochloride | LMF-237 | Approved | Novartis Pharma Ag | 宜合瑞, Eucreas, EquMet, Zomarist, Icandra | Japan | Diabetes Mellitus, Type 2 | Novartis Pharma Ag | 2007-11-14 | Diabetes Mellitus, Type 2 | Details |
Sitagliptin Phosphate Monohydrate/Ipragliflozin L-Proline | MK-0431J | Approved | Merck & Co Inc, Astellas Pharma Inc | Sujanu | Japan | Diabetes Mellitus, Type 2 | null | 2018-03-23 | Diabetes Mellitus, Type 2 | Details |
Alogliptin Benzoate | SYR-322; TAK-322 | Approved | Takeda | Nesina, 尼欣那, Vipidia | EU | Diabetes Mellitus, Type 2 | Takeda Pharma A/S | 2010-04-06 | Diabetes Mellitus, Type 2; Acute Coronary Syndrome; Diabetes Mellitus | Details |
Evogliptin | DA-1229 | Approved | Dong-A Pharmaceutical Co Ltd | Suganon, Sugarnon | South Korea | Diabetes Mellitus, Type 2 | Dong-A Pharmaceutical Co Ltd | 2015-10-02 | Diabetes Mellitus, Type 2; Kidney Diseases; Aortic valve diseases; Liver Diseases | Details |
Teneligliptin Hydrobromide Hydrate | MP-513 | Approved | Mitsubishi Tanabe Pharma | Tenelia, Tenglyn | Mainland China | Diabetes Mellitus, Type 2 | Mitsubishi Pharma Research & Development (Beijing) Co Ltd | 2012-06-29 | Diabetes Mellitus, Type 2 | Details |
Saxagliptin Hydrate | BMS-477118; BMS-477118-11; OPC-262 | Approved | Bristol-Myers Squibb Company | 安立泽, Onglyza | Japan | Diabetes Mellitus, Type 2 | Kyowa Hakko Kirin Co Ltd | 2009-07-31 | Diabetes Mellitus, Type 1; Diabetes Mellitus, Type 2; Hypoglycemia; Diabetes Mellitus | Details |
English Name | Research Code | Research Phase | Company | Indications | Clinical Trials |
---|---|---|---|---|---|
TSL-0319 | TSL-0319 | Phase 1 Clinical | Jiangsu Tasly Diyi Pharmaceutical Co Ltd | Diabetes Mellitus, Type 2 | Details |
WXSHC-071 | WXSHC-071 | Phase 1 Clinical | Dongbao Zixing (Hangzhou) Biological Medicine Co Ltd | Diabetes Mellitus, Type 2 | Details |
Cetagliptin Phosphate | CGT-8012 | Phase 3 Clinical | Cgenetech(Suzhou China) Co Ltd | Diabetes Mellitus, Type 2 | Details |
TQ-05510 | TQ-05510 | Phase 1 Clinical | Jiangsu Chia Tai-Tianqing Pharmaceutical Co Ltd, Centaurus Biopharma Co Ltd | Diabetes Mellitus, Type 2 | Details |
Augliptin Hydrochloride | Phase 1 Clinical | Shanghai Sun-Sail Pharmaceutical Science & Technology Co Ltd, Nanjing Changao Pharmaceutical Science And Technologyco Ltd | Diabetes Mellitus, Type 2 | Details | |
Carmegliptin | R-1579; RG-1579; DPP-IV(3); RO-4876904; RO-4876904-001 | F. Hoffmann-La Roche Ltd | Details | ||
Linagliptin/Fimasartan Potassium Trihydrate | Boryung Pharmaceutical Co Ltd | Details | |||
Gosogliptin | PF-734200; PF-00734200 | Pfizer Pharmaceuticals Ltd (China) | Details | ||
CPL2009-0031 | Cadila Healthcare Ltd | Details | |||
Lobeglitazone/Sitagliptin | CKD-396 | Chong Kun Dang Pharmaceutical Corp | Details | ||
Melogliptin | GRC-8200; EMD-675992 | Glenmark Pharmaceuticals Ltd | Details | ||
BMS-767778 | BMS-767778 | Bristol-Myers Squibb Company | Details | ||
Begelomab | SAND-26; BT 5/9 | Phase 2 Clinical | Adienne | Dermatomyositis; Graft vs Host Disease | Details |
TQ-F3083 | TQ-F3083 | Phase 2 Clinical | Jiangsu Chia Tai-Tianqing Pharmaceutical Co Ltd, Centaurus Biopharma Co Ltd | Diabetes Mellitus, Type 2; Diabetes Mellitus | Details |
Yogliptin | Phase 3 Clinical | Sichuan Sunheal Pharmaceutical Co Ltd, Chengdu Easton Biopharmaceuticals Co Ltd | Diabetes Mellitus, Type 2 | Details | |
Metformin/Dapagliflozin/Sitagliptin | GMRx4 | Phase 2 Clinical | George Medicines PTY Ltd, George Medicines UK Ltd | Diabetes Mellitus, Type 2 | Details |
DC291407 | DC-407; DC-291407 | Phase 2 Clinical | Cisen Pharmaceutical Co Ltd, Shanghai Institute Of Materia Medica, Chinese Academy Of Sciences | Diabetes Mellitus, Type 2; Fatty Liver | Details |
Empagliflozin/Metformin/Sitagliptin | Phase 1 Clinical | Taizhou Overseas Pharmaceuticals Co Ltd | Diabetes Mellitus, Type 2 | Details | |
Sitagliptin/Telmisartan | HDDO-16091 + HDDO-16092; HOB-077; HDDO-1609 | Phase 1 Clinical | Hyundai Pharmaceutical Co Ltd | Hypertension; Diabetes Mellitus | Details |
REC-04 | Clinical | Recardio Inc | Cardiovascular Diseases | Details | |
Dutogliptin Tartrate/Metformin Hydrochloride | Phenomix Corporation | Details | |||
Evogliptin Tartrate | LY-05007 | Phase 1 Clinical | Dong-A Pharmaceutical Co Ltd | Diabetes Mellitus, Type 2 | Details |
THDBH-100 | THDBH100; THDBH101 | Phase 1 Clinical | Wuxi Apptec(Shanghai) Co Ltd | Diabetes Mellitus, Type 2 | Details |
Dutogliptin Tartrate | REC-01; PHX-1149; PHX-1149T | Phase 2 Clinical | Phenomix | Diabetes Mellitus, Type 2; Myocardial Infarction; ST Elevation Myocardial Infarction; Kidney Diseases; Leukemia, Myeloid, Acute | Details |
Retagliptin Phosphate/Metformin Hydrochloride | HRX-0701 | Phase 1 Clinical | Jiangsu Hengrui Medicine Co Ltd | Diabetes Mellitus, Type 2 | Details |
Bogliptin maleate | HL012MA | Phase 2 Clinical | Shanghai Institute Of Materia Medica, Chinese Academy Of Sciences, East China University Of Science And Technology, Shandong Baiji Dichang Pharmaceutical Co Ltd | Diabetes Mellitus, Type 2 | Details |
HSK-7653 | HSK7653; HSK-7653 | Phase 3 Clinical | Liaoning Haisco Pharmaceutical Co Ltd, Sichuan Haisco Pharmaceutical Co Ltd | Diabetes Mellitus, Type 2; Glucose Intolerance; Kidney Diseases | Details |
TOTUM•63 | TOTUM-63 | Phase 3 Clinical | Valbiotis | Diabetes Mellitus, Type 2 | Details |
Dapagliflozin/Sitagliptin | SID-1903; DW-6012 | Phase 1 Clinical | Astrazeneca Sa | Diabetes Mellitus, Type 2 | Details |
Diabetes therapeutic | DBPR-108 | Phase 3 Clinical | Taiwan Shenlong Co Ltd, National Health Research Institutes | Diabetes Mellitus, Type 2; Kidney Diseases; Hepatic Insufficiency | Details |
Fotagliptin Benzoate | FCN-005 | Phase 3 Clinical | Fochon Pharmaceuticals Ltd, Shanghai Fosun Pharmaceutical (Group) Co Ltd | Diabetes Mellitus, Type 2 | Details |
Talabostat | PT-100; BXCL-701 | Phase 2 Clinical | Midatech Pharma Plc, Bioxcel Therapeutics Inc | Neuroblastoma; Melanoma; Leukemia, Lymphocytic, Chronic, B-Cell; Adenocarcinoma; Neoplasms, Germ Cell and Embryonal; Carcinoma, Non-Small-Cell Lung; Neoplasm Metastasis; Carcinoma, Pancreatic Ductal; Lung Neoplasms; Carcinoma, Small Cell; Brain Neoplasms; Solid tumours; Sarcoma; Prostatic Neoplasms; Central Nervous System Neoplasms; Neuroendocrine Tumors; Skin Neoplasms; Pancreatic Neoplasms; Kidney Neoplasms; Ovarian Neoplasms; Liver Neoplasms | Details |
This web search service is supported by Google Inc.